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Clinical Trial of Oral Naltrexone Versus Placebo
Robert L. Cook, Zhi Zhou
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Babette Brumback, and Kendall Bryant

Background: Alcohol consumption is associated with poor health outcomes in women living with
HIV (WLWH), but whether medication can help to reduce drinking in non–treatment-seeking women
or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current
unhealthy alcohol use.
Methods: WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were
randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking
outcomes, including the proportion of women who reduced (<unhealthy use criteria) or quit drinking,
were assessed at baseline, 2 months, 4 months (end of treatment), and 7 months. In a secondary analysis, HIV viral suppression and changes in CD4 counts were compared in women who did or did not
reduce/quit drinking, regardless of intervention assignment.
Results: The participants’ mean age was 48 years, 86% were African American, and 94% were
receiving HIV antiretroviral therapy. Among all participants, 89% and 85% completed the 4-month
and 7-month follow-ups, respectively. Participants in both groups substantially reduced drinking over
time. At 1 and 3 months, naltrexone was associated with a greater reduction in drinking (p < 0.05), but
the proportion who reduced/quit drinking at 4 months (52% vs. 45%, p = 0.36) or 7 months (64% in
both groups) was not diﬀerent. HIV viral suppression at follow-up was signiﬁcantly better in participants who reduced/quit drinking versus those continuing unhealthy alcohol use at 4 months (72% vs.
53%, p = 0.02) and 7 months (74% vs. 54%, p = 0.02).
Conclusions: Participating in an RCT to reduce drinking was associated with signiﬁcant drinking
reduction regardless of medication assignment, suggesting that nonmedication aspects of research study
participation (e.g., repeated assessments and support from research staﬀ) could be important interventions to help reduce drinking outside of research studies. Drinking reduction was associated with
improved HIV viral suppression, providing evidence to support recommendations to avoid unhealthy
alcohol use among WLWH.
Key Words: Alcohol Consumption, HIV Infection, Randomized Clinical Trial, Women,
Pharmacotherapy.
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A

MONG PERSONS LIVING with HIV infection,
antiretroviral therapy (ART) can suppress the level of
HIV in the blood to undetectable levels, which reduces HIV
transmission and improves survival. Despite the availability
of ART, many do not achieve HIV viral suppression, with
women being less likely than men to achieve HIV viral suppression (Aziz and Smith, 2011; Chakraborty et al., 2015).
Women account for approximately 23% of new HIV infections in the United States (Centers for Disease Control and
Prevention, 2016), and strategies are needed to reduce HIV
outcome disparities among women living with HIV/AIDS
(WLWH).
Alcohol reduction is one possible strategy to improve
health outcomes in WLWH. Unhealthy alcohol use, deﬁned
as >7 drinks/wk or >3 drinks/occasion for women (National
Institute on Alcohol Abuse and Alcoholism, 2008), is
reported by approximately 6 to 25% of WLWH (Cook
et al., 2013; Theall et al., 2007). Unhealthy alcohol use is
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associated with poor medication adherence, less HIV viral
suppression, more rapid HIV disease progression, and
increased hospitalization rates (Deiss et al., 2016; Hahn and
Samet, 2010; Kader et al., 2015; Rentsch et al., 2016).
Alcohol consumption is also associated with chronic disease
outcomes that are more common in persons with HIV,
including liver disease, cardiovascular disease, and cancer
(Cao et al., 2015; Gao and Bataller, 2011; Kelso et al., 2015;
Park et al., 2016; Smith et al., 2014). Longitudinal studies
suggest that increases in drinking among WLWH can result
in worse HIV-related clinical outcomes (Barai et al., 2017;
Williams et al., 2018). However, little hard evidence suggests
that reductions in drinking will correlate with improved
HIV-related health outcomes. Several medications are
FDA-approved to help reduce drinking, yet they are not
prescribed very often (Chander et al., 2016). Moreover,
relatively few clinical trials of alcohol pharmacotherapy
included large numbers of women (Canidate et al., 2017),
most excluded persons who had comorbid mental health
or other substance use behavior, and none examined clinical outcomes related to HIV infection. Therefore, we
sought to understand how pharmacotherapy for alcohol
consumption might work when oﬀered to a broad, generalizable sample of WLWH who currently exceed recommended drinking levels.
We previously completed a pilot study to demonstrate that
WLWH were willing to enroll in a clinical trial of naltrexone
versus placebo and that many women could successfully
reduce their drinking during the study (Cook et al., 2017).
We selected naltrexone rather than other existing medications because it can be taken once daily and is generally well
tolerated (Jonas et al., 2014; Maisel et al., 2013), and
because it can be used to support either alcohol reduction or
complete cessation (Tidey et al., 2008). However, the pilot
study was not powered to determine the overall eﬀect of naltrexone in this population, or whether reductions in drinking
could improve HIV-related outcomes.
Therefore, the speciﬁc objectives of this study were to determine the eﬀects of naltrexone versus placebo on drinking
behavior and clinical outcomes in WLWH. We planned subgroup analyses to compare study outcomes by baseline severity of drinking and by adherence to the study protocol, and
we also planned a secondary analysis to compare HIV clinical
outcomes in women who did or did not reduce or quit drinking during the trial, regardless of intervention assignment.

MATERIALS AND METHODS
Overview
The WHAT-IF? (Will Having Alcohol Treatment
Improve my Functioning?) study was a double-blind randomized clinical trial in which eligible women received either
naltrexone 50 mg orally or placebo for 4 months, allocated
in a 1:1 ratio, with follow-up assessments at 2, 4, and
7 months. The study was approved by IRBs at the
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University of Miami Miller School of Medicine, Florida
International University, and the University of Florida and
was registered on ClinicalTrials.gov (NCT01625091). Prior
to study initiation, all study staﬀ completed detailed training
about the study procedures.
Participants and Setting
Participants were recruited from a range of clinical and
community-based settings in Miami, Florida, from 2013 to
2016. Recruitment strategies included leaving brochures in
clinical settings, contacting participants from previous
research studies, and referral from other participants. We did
not recruit directly from alcohol treatment settings because
women receiving other current treatments for alcohol consumption were excluded. WLWH were eligible if they were
18 years or older and met past-month criteria for unhealthy
alcohol use (>7 drinks/wk or >3 drinks on one single day at
least twice) (National Institute on Alcohol Abuse and Alcoholism, 2008). Exclusion criteria included contraindications
to using naltrexone (current opiate dependence, current prescription opioid medications, positive urine drug screen for
opioids, and/or allergic to naltrexone); elevated liver
enzymes, serum creatinine, or blood pressure at the time of
enrollment; currently pregnant; currently taking a medication for alcohol treatment, tuberculosis, or viral hepatitis;
unable to understand English or the study procedures; current prognosis of less than 1 year to live (e.g., metastatic cancer); or recommendation from a study physician based on
other information available at the time of enrollment.
Study Procedures
At the enrollment visit, participants learned about the
study, signed the informed consent and HIPAA forms, and
provided a urine sample to conﬁrm they were not pregnant
or using opioids. Eligible participants were then scheduled
for a baseline assessment that included a limited clinical
assessment by a research nurse (blood pressure, height and
weight, and repeated urine test for opioids), completion of
study questionnaires, a blood draw, randomization, and initiation of study medication.
The baseline assessment questionnaire was completed by
participants using an audio computer-assisted self-interview
(ACASI) computer program, in which women entered their
own information with assistance from a research assistant if
needed. The questionnaire assessed sociodemographic characteristics including age, race/ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or non-Hispanic other),
marital status, employment, and education (less than high
school, high school graduate, some college, or college graduate). The baseline questionnaire also inquired about the frequency of use of 9 other classes of drugs and tobacco
products. Recent drug use was deﬁned as any self-reported
use of benzodiazepines, cocaine, amphetamines, marijuana,
opioids, or hallucinogens in the past 30 days. Risky sexual
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behavior was deﬁned as having unprotected sexual intercourse with a male who was HIV-discordant or of unknown
HIV status in the past year (Cook et al., 2010). Adherence to
HIV ART was self-reported as the percentage of prescribed
HIV medication that participants took in the last 30 days
(Badiee et al., 2012).
The timeline follow-back (TLFB) (Sobell and Sobell,
1992) was used to calculate the average number of drinks per
week, the number of days of abstinence, and the number of
binge-drinking days in the 30 days prior to study initiation.
At baseline, participants also completed the Alcohol Use
Disorders Identiﬁcation Test (AUDIT) (Saunders et al.,
1993) and the Short Inventory of Problems (SIP), a 15-item
measure of consequences of drinking (score 0 to 60) (Miller
et al., 1985). Craving for alcohol was measured by a single
item scored 1 to 10, with 10 being strongest craving. A computerized version of the Mini-International Neuropsychiatric
Interview (MINI) (Sheehan et al., 1998) was used to assess
for alcohol abuse and/or dependence based on DSM-IV criteria.
Blood samples were obtained and sent to a commercial
laboratory to assess CD4 + count, HIV viral load, and a
comprehensive metabolic panel. HIV viral suppression was
deﬁned as <200 copies/ml (or undetectable). A dried blood
spot was sent to a commercial laboratory (USDTL, Des
Plaines, IL) to test for phosphatidylethanol (PEth), a biomarker of heavy alcohol use over the previous 3 weeks
(Aradottir et al., 2006).
Randomization and Intervention
This clinical trial was double-blinded, so neither the participants nor research staﬀ knew who received naltrexone or
placebo. A computer-generated randomization sequence,
created by the study biostatistician, assigned each consecutive study ID number to either naltrexone or placebo in
blocks of 8 ID numbers (4 naltrexone and 4 placebo). Eligible participants were each assigned the next consecutive
study ID number when they enrolled, and they received the
medication assigned to that ID number.
The study medication was provided by a certiﬁed compounding pharmacy, who produced identical-appearing
capsules for naltrexone and placebo (WELLHealthrx,
Jacksonville, FL). The active medication contained 50 mg
naltrexone/pill, and the placebos were identical-appearing
pills of inert cellulose. Study medications were stored and
distributed by the research pharmacy at the University of
Miami Miller School of Medicine, who had access to
information linking study ID number and study medication. At the baseline visit, participants took the ﬁrst pill
and remained with the research staﬀ for 30 minutes to
make sure they did not have an acute, allergic reaction.
The research team then provided a 30-day supply of
study medication contained within 30-pill blister packets,
and participants were asked to punch out and take one
pill daily for 4 months.

Follow-up Procedures
After enrollment, research staﬀ maintained regular contact
with study participants to encourage adherence to the study
medication and to monitor for adverse events. Participants
were assessed weekly for the ﬁrst month (weeks 1 and 3 by
telephone and weeks 2 and 4 in-person) and then in-person
monthly until the 4-month visit, at which time participants
were asked to stop the study medication. A ﬁnal follow-up
was completed 7 months after enrollment. Participants
received incentive payments for each in-person assessment to
encourage follow-up and to support the time and inconvenience of completing the assessments.
At each follow-up assessment, research staﬀ used a series
of counseling checklists, based on a study manual developed
for another naltrexone clinical trial (Pettinati and Mattison,
2010) to help promote adherence to the study medication. At
the in-person visits, research staﬀ also provided reﬁlls on
study medication and collected updated drinking data by
TLFB. Research staﬀ were trained to be neutral in their alcohol assessments to minimize social desirability bias. Research
staﬀ also collected data about study medication adherence,
assisted by visual inspection of the punch-out pill packs, to
determine the proportion of study medication taken (the
number of doses taken divided by the number prescribed).
Participants completed follow-up ACASI questionnaires
during in-person visits at 2, 4, and 7 months. The follow-up
questionnaires included repeated measures from baseline,
including questions about HIV medication adherence, other
substance use, and sexual activity. Follow-up laboratory
tests for HIV viral load, CD4 + count, and liver and kidney
function were obtained at 2 weeks, 2 months, 4 months, and
7 months. Follow-up PEth testing was conducted at 2 and
7 months.
Safety Monitoring
In addition to regular monitoring of participant liver and
kidney function, the research staﬀ collected information
about potential adverse events that were reported by participants on their own or after prompting from a speciﬁc assessment designed to track potential side eﬀects (Johnson et al.,
2005). The research team evaluated each potential adverse
event, determined whether the event appeared to be related
to the study medication, and tracked events until resolution.
Adverse events were deﬁned as any side eﬀect or clinical
event that was not present at baseline or became more severe
compared to baseline. The research team informed participants about abnormal laboratory results that a study physician deemed to be of potential clinical signiﬁcance. A data
safety and monitoring board (DSMB) consisting of 3 members independent from the research team reviewed study
results and adverse events annually. The DSMB was also
consulted to help evaluate persons with serious adverse
events during follow-up and to help make recommendations
regarding the progress of the study.
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Statistical Analysis
We originally proposed to enroll 240 women (160 treatment, 80 control), which would provide 82% power to detect
a shift in mean weekly alcohol consumption of 0.4 standard
deviations. The study design was changed to a 1:1 allocation
before study initiation, and after approximately 100 women
had enrolled, the DSMB approved a revised sample size of
200 (100 per treatment group), which would generate a similar eﬀect size, based on better-than-expected retention.
Baseline characteristics were compared between subjects
randomized to the naltrexone and placebo groups. t-Tests
and Wilcoxon–Mann–Whitney tests were used to assess differences in means and medians, respectively, whereas the chisquare test was used for categorical variables. Primary and
secondary outcomes were determined a priori and measured
at the 4-month time point, which coincided with completion
of study medication. The primary outcome was “reduced/
quit drinking,” deﬁned as either reduction of drinking to less
than unhealthy amounts (i.e., 7 or fewer drinks per week and
3 or fewer drinks on every day in the past 30 days) or completely stopping drinking. Secondary drinking outcomes
included the number of abstinent days and the number of
binge-drinking days in the past 30 days, the total score on
the SIP (range 0 to 60), and the craving score for alcohol
(range 1 to 10). Clinical and behavioral outcomes included
HIV viral suppression (<200 copies/ml), mean CD4 + count,
change in CD4 + count (baseline to follow-up), and HIV
medication adherence (>95%). We conducted statistical
comparisons for each outcome at speciﬁc time points, using
chi-square and t-tests where appropriate. We compared the
proportion of persons with continued unhealthy alcohol use
monthly for the 4 months of treatment to explore patterns of
changes over time. The primary outcome analyses at
4 months (end of treatment) and 7 months (end of study)
used logistic regression to estimate the odds of reducing/quitting drinking in naltrexone versus placebo, based on intention-to-treat. The primary analyses were unadjusted, but we
also did analyses adjusting for baseline alcohol use disorder,
since it was signiﬁcantly diﬀerent in the 2 groups at baseline.
We also conducted preplanned subgroup analyses stratiﬁed
by alcohol dependence at baseline (yes or no), PEth results at
baseline (≥8 or <8 ng/ml), and adherence to the study medication (≥90% or <90% of doses taken over 4 months). If any
results appeared to be signiﬁcant by subgroup status, we
included an interaction term in a regression model to test for
statistical signiﬁcance.
Finally, we conducted an observational analysis to compare the HIV-related outcomes in women who successfully
reduced/quit drinking at the end of the study (7 months),
compared to those who continued unhealthy alcohol use,
regardless of their intervention assignment. For this analysis, we used a propensity-weighted logistic regression
approach in which we adjusted for treatment assignment
(naltrexone or placebo) and baseline variables that were
associated with the primary outcome at p < 0.02 at the
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7-month time point (Brookhart et al., 2006). All analyses
were performed in SAS 9.4., SAS Institute, Inc., Cary,
NC, USA.
RESULTS
Of 221 women with current alcohol consumption who
spoke to clinical or research staﬀ about the study, 27 were
either ineligible or lost to follow-up (Fig. 1). Of the remaining 194 women, 96 were enrolled and randomized to naltrexone and 98 to placebo. Of those enrolled, 172 (89%)
completed the 4-month assessment, and 165 (85%) completed the 7-month assessment. Overall, 112 (66%) women
reported taking 90% of the recommended doses of study
medication over the 4-month period (60% in the naltrexone
group versus 72% in the placebo group, p = 0.08).
Baseline characteristics of study participants by randomization assignment are shown in Table 1. The participants
were primarily middle-aged (mean age 48 years, SD = 9)
and African American (83%). At baseline, participants
reported an average of 66 standard drinking units (SDU) per
week and an average of 18 binge-drinking days in the
30 days prior to enrollment. All participants met criteria for
unhealthy alcohol use; the mean AUDIT score was 17, 62%
met criteria for an alcohol use disorder, and 47% had a positive PEth alcohol biomarker at baseline (>8 ng/ml). Only
63% had HIV viral suppression at enrollment, and the mean
CD4 + count was 556 cells/ml (SD = 346). Most participants also reported current smoking (63%) or other drug use
(58%), whereas very few reported risky sexual behavior in
the past 12 months. No demographic or behavioral characteristics were signiﬁcantly diﬀerent by intervention assignment. However, current alcohol use disorder was more
common in subjects assigned to naltrexone compared to placebo (71% vs. 53%, p < 0.05).
During follow-up, the proportion of subjects with
unhealthy alcohol use declined in both groups. Only about
50% of women reported ongoing unhealthy alcohol use at
4 months, and the proportion with unhealthy alcohol use
continued to drop even after medication was stopped
(Fig. 2). While the proportions of women with unhealthy
alcohol use were statistically similar at the primary endpoint of 4 months (p = 0.36), the naltrexone group
demonstrated signiﬁcantly lower levels of unhealthy drinking at 1 month (p = 0.045) and 3 months (p = 0.03) after
enrollment (Fig. 2). For the main endpoint at 4 months,
the unadjusted odds of reducing/quitting drinking for
women receiving naltrexone versus placebo was 1.32 (95%
CI 0.73, 2.41, p = 0.36). With adjustment for baseline
alcohol use disorder, the odds ratio was 1.47 (95% CI
0.79, 2.74, p = 0.23).
Regarding other drinking outcomes, both study groups
demonstrated substantial decreases in the average number of
drinks per week, the number of binge-drinking days per
month, and craving for alcohol (Table 2). Consequences
related to drinking, as measured by the SIP, were reduced by
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Fig. 1. Participant flowchart.

nearly half in both groups (Table 2). Both groups also
demonstrated signiﬁcant increases in the number of abstinent
days per month (Table 2). These drinking outcomes were
not statistically diﬀerent between treatment groups (naltrexone vs. placebo). Similarly, the HIV clinical outcomes,
including the proportion of women with HIV viral suppression, the mean CD4 count+, or self-reported ART adherence, did not diﬀer during follow-up in women receiving
naltrexone versus placebo (Table 2).
Subgroup Analyses
In subgroup analyses, naltrexone appeared to be superior
to placebo in reducing unhealthy drinking in women with
alcohol dependence at baseline (n = 92), but not in women
without alcohol dependence at baseline (n = 79), although
the interaction of naltrexone and baseline alcohol dependence was not statistically signiﬁcant (Table 3). The primary
outcome did not diﬀer by treatment group according to the
presence of a positive PEth alcohol biomarker at baseline,
adherence to the study medication during follow-up, or age
(Table 3).

Adverse Events
Adverse events that appeared to be related to the study
medications were common. Although the diﬀerences were
not statistically signiﬁcant (51% vs. 41%, p = 0.19), side
eﬀects tended to be more common in women receiving naltrexone, especially for gastrointestinal symptoms such as nausea, abdominal pain, diarrhea, and vomiting (Table 4).
Severe adverse events occurred in 11 participants in the naltrexone group (1 death and 10 inpatient hospitalizations) and
8 in the placebo group (2 deaths and 6 inpatient hospitalizations). None of these was determined to be related to the
study medication. Four participants in the naltrexone group
and 2 in the placebo group stopped taking the study medication due to possible drug-related adverse events (nausea/vomiting, itchiness, elevated liver enzymes, and constipation).

Relationship of Drinking Reduction to HIV Clinical
Outcomes: Secondary Analysis
HIV viral load and CD4 + counts were compared in
subjects who successfully reduced/quit drinking at the ﬁnal
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Table 1. Baseline Characteristics of 194 Women With HIV According to
Treatment Assignment

Baseline characteristics

Total
(N = 194)

Sociodemographics
Age (mean  SD)
48  9
Age-group (%)
18 to 39
29 (15)
40 to 49
67 (35)
50 to 59
80 (41)
≥60
18 (9)
Race/ethnicity (%)
Hispanic
22 (11)
Non-Hispanic white
8 (4)
Non-Hispanic black
161 (83)
Non-Hispanic other
3 (2)
Married or in a long-term 31 (16)
relationship
Employed
20 (10)
Education (%)
Less than high school
84 (43)
High school graduate
66 (34)
Some college or college 44 (23)
graduate
Alcohol consumption
Number of standard drinks 66  78
per week (mean  SD)
Abstinent days in the past 9  8
30 days (mean  SD)
Binge-drinking days in the 18  9
past 30 days (mean  SD)
Alcohol
craving
score 5.9  2.9
(mean  SD)
SIP score (mean  SD)
12.9  11.1
AUDIT score (mean  SD)
17  8
Alcohol use disorder (%)
No
74 (38)
Alcohol abuse only
16 (8)
Alcohol dependence
103 (53)
PEth value (%)
<8 ng/ml
102 (53)
8 to 20 ng/ml
18 (9)
>20 ng/ml
74 (38)
HIV clinical and other behavioral factors
HIV
viral
suppression 119 (63%)
(<200 copies/ml)
CD4 count (mean  SD)
556  346
Currently on ART
182 (94%)
≥95% ART adherence in the 98 (61%)
a
past 30 days
BSI grand total score 28.6  32.4
(mean  SD)
Tobacco use in the past 120 (63%)
30 days
Any drug use in the past 30 109 (58%)
days
Risky sexual behavior in the 13 (7%)
past 12 months

Naltrexone
(n = 96)

Placebo
(n = 98)

48  8

49  9

16 (17)
35 (36)
37 (39)
8 (8)

13 (13)
32 (33)
43 (44)
10 (10)

11 (11)
3 (3)
81 (84)
1 (1)
16 (17)

11 (11)
5 (5)
80 (82)
2 (2)
15 (15)

11 (11)

9 (9)

40 (42)
38 (40)
18 (19)

44 (45)
28 (29)
26 (27)

58  51

73  97

88

98

19  9

18  10

6.0  3.0

5.8  2.7

13.1  11.4
17  8

12.7  10.9
16  8

28 (29)
11 (12)
56 (59)

46 (47)*
5 (5)
47 (48)

49 (51)
10 (10)
37 (39)

53 (54)
8 (8)
37 (38)

57 (61%)

62 (65%)

541  295
91 (95%)
47 (59%)

571  391
91 (93%)
51 (63%)

27.4  32.6

29.7  32.2

61 (64%)

59 (61%)

56 (59%)

53 (58%)

7 (7%)

6 (6%)

SD, standard deviation; BSI, Brief Symptom Inventory.
a
Among participants who were currently on ART.
*p < 0.05 by chi-square test.

7-month time point compared to those who continued
unhealthy alcohol use at the end of the study. As shown in
Fig. 3, women who ultimately reduced/quit drinking
(n = 106, 64%) tended to have improved viral suppression
over time, whereas women who continued to drink at
unhealthy levels (n = 60, 36%) tended to get slightly worse

over time. The proportion of women with viral suppression
was statistically signiﬁcantly better in the women who successfully reduced/quit at both the 4-month and 7-month time
points, compared to those who continued to drink at
unhealthy levels (Fig. 3). In a propensity-weighted logistic
regression model, the odds of having successful viral suppression at 7 months were signiﬁcantly greater in women who
had reduced/quit drinking compared to those who did not
(OR 2.53, 95% CI 1.04 to 6.18). This model adjusted for
treatment assignment (naltrexone or placebo) and other variables that were associated with HIV viral suppression at the
7-month time point, including AUDIT-10 score, number of
abstinent days at baseline, ART use, tobacco use, and baseline HIV viral suppression. Overall, the average
CD4 + counts were stable during the 7 months of study
observation, and no signiﬁcant changes occurred overall in
persons who quit/reduced drinking or in those who continued to drink (data not shown).
DISCUSSION
We sought to determine whether oral naltrexone would
be eﬀective in reducing drinking in WLWH, many of
whom have multiple medical, psychiatric, and substance
abuse comorbidities that would typically exclude them
from alcohol pharmacotherapy clinical trials. We also
sought to determine whether a reduction in drinking
would be associated with improved HIV clinical outcomes.
Overall, naltrexone was not associated with improvements
in the primary endpoint of reduction in unhealthy alcohol
use after 4 months of treatment. However, naltrexone was
associated with statistically signiﬁcant reductions in the
average number of drinks per week at 1 month and
3 months after enrollment, and naltrexone also appeared
to be superior to placebo in women with symptoms of
alcohol dependence at baseline.
Overall, the drinking results are similar to those of
other studies comparing naltrexone to placebo, which tend
to demonstrate mild or modest improvements for naltrexone when compared to placebo (Canidate et al., 2017;
Kranzler and Soyka, 2018). However, these modest
improvements should be balanced by a relatively high
number of persons who experience side eﬀects such as
nausea and vomiting (Sinclair et al., 2016). The fact that
94% of study participants were African American is diﬀerent from most previous alcohol trials. Previous data suggest that naltrexone may not be as eﬀective in African
Americans than other racial groups (Bress et al., 2015;
Ray and Oslin, 2009), and this could have contributed to
the relative lack of an eﬀect in our study.
Ultimately, one of the primary goals of drinking reduction is to improve overall health outcomes. Most clinical
trials involving naltrexone have only examined its eﬀect
on drinking, although reanalysis of at least one study one
study demonstrated that reduction in drinking among clinical trial participants is accompanied by improvements in
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Fig. 2. Proportions of participants with continued unhealthy drinking in the past 30 days among 194 women with HIV. Participants received treatment
(naltrexone or placebo) for 4 months.

clinical health such as blood pressure, liver enzymes, and
quality of life (Witkiewitz et al., 2018). Two recent studies
sought to determine whether naltrexone or other alcoholrelated therapy can improve HIV outcomes, one of which
found that reductions in drinking were associated with
improved HIV viral suppression (Edelman et al., 2018;
Springer et al., 2018).
The fact that women receiving placebo did so well is striking. Placebo eﬀects have been noted across a range of alcohol
clinical trials and could be greater in those with less severe
conditions at baseline (Litten et al., 2013). Placebo eﬀects
can be biological (e.g., the target receptors are activated) or
psychological (e.g., expectancies and/or conditioning) (Finniss et al., 2010). The reduction in drinking in both groups
also suggests that other aspects of research study participation could be equally or more important than the speciﬁc
pharmacologic medication for overall drinking reduction.
Women in this study may have chosen to participate in a
clinical trial related to drinking because they were already
interested in quitting. Although we did not directly inquire
whether participants were treatment-seeking, many participants may have been interested in reducing or stopping their
drinking and waiting for the right opportunity to attempt to
change their drinking (Cook et al., 2017). All women
received multiple assessments related to alcohol consumption
and its consequences, and reliable evidence suggests that
repeated assessments alone can have an impact on overall
drinking behavior (McCambridge and Kypri, 2011). This
study had consistent research staﬀ throughout the study, and
many participants commented that the study staﬀ seemed to
care about them as persons, beyond being just a participant
in a research study. Such social support could also be a
mechanism to help women succeed in changing their drinking behavior.

Our data suggest that a reduction in drinking to less
than unhealthy levels can result in improved HIV-related
clinical outcomes for women, regardless of the speciﬁc
medication used. While other observational data from
clinical trials or longitudinal cohorts have shown increases
in drinking to be associated with worse HIV clinical outcomes, little evidence suggests that reductions in drinking
are associated with improved HIV-related outcomes such
as HIV viral suppression (Barai et al., 2017; Williams
et al., 2018). One challenge with traditional longitudinal
alcohol studies is that persons may reduce drinking
because they have become sicker, causing it to appear that
quitting drinking may be more harmful than beneﬁcial
(Williams et al., 2018). Of note, a recently reported clinical
trial of stepped integrated alcohol treatment within the
VA healthcare system reported that persons receiving an
alcohol intervention did have improved HIV viral suppression, compared to usual care, although that study sample
was 98% male (Edelman et al., 2019).
One of the major limitations in this and nearly every
other randomized clinical trial to change alcohol consumption is that the primary outcome is based on self-report.
We attempted to maximize our self-reported outcomes by
training our staﬀ to conduct a detailed TLFB. Although
we encouraged research staﬀ to be neutral, it is always
possible that women reported reductions in drinking to
please study staﬀ. The study recruited slightly fewer
women than originally intended, which could have aﬀected
the ability to detect statistically signiﬁcant changes in
drinking. However, the decision to stop the study with
slightly less than the originally planned enrollment was
supported by review of an updated power analysis by the
study DSMB, who noted that retention was better than
predicted. Notably, only about 50% of participants had a
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Table 2. Primary and Secondary Outcomes at Baseline, 4 Months, and 7
Months
Naltrexone N=(96)

Placebo (n = 98)

Alcohol consumption
Reduced/quit drinking
Baseline
0 (0%)
0 (0%)
4 months
44 (52%)
39 (45%)
7 months
52 (64%)
54 (64%)
Number of standard drinks per week (mean  SD)
Baseline
58  51
73  97
4 months
11  20
18  42
7 months
7  14
11  31
Binge-drinking days in the past 30 days (mean  SD)
Baseline
19  9
18  10
4 months
48
48
7 months
36
48
Alcohol craving score (mean  SD)
Baseline
6.0  3.0
5.8  2.7
4 months
3.3  3.4
3.2  2.9
7 months
2.2  3.0
2.6  3.0
SIP score (mean  SD)
Baseline
13.1  11.4
12.7  10.9
4 months
7.2  9.9
6.7  8.4
7 months
5.7  8.9
5.9  8.7
Abstinent days in the past 30 days (mean  SD)
Baseline
88
98
4 months
23  10
22  10
7 months
25  9
24  9
HIV clinical characteristics
HIV viral suppression (<200 copies/ml)
Baseline
57 (61%)
62 (65%)
4 months
56 (68%)
58 (67%)
7 months
53 (67%)
57 (70%)
CD4 + count (mean  SD)
Baseline
541  295
571  391
4 months
544  311
609  384
7 months
527  295
592  433
Change of CD4 + count from baseline (mean  SD)
4 months
7 (130)
25 (184)
7 months
3 (138)
8 (213)
≥95% ART adherence in the past 30 daysa
Baseline
47 (59%)
51 (63%)
4 months
48 (63%)
51 (70%)
7 months
44 (60%)
50 (66%)

Table 3. Impact of Naltrexone on 4-Month Unhealthy Alcohol Use:
Subgroup Analyses

p-Value*

Quit or reduced drinking (%)
Naltrexone (n = 85)

na
0.36
0.93
0.18
0.19
0.24
0.20
0.77
0.32
0.57
0.98
0.46

Alcohol dependence (%)
Yes (n = 92)
28 (56)
No (n = 79)
16 (47)
PEth value (%)
Positive, ≥8 ng/ml
19 (46)
(n = 80)
Negative, <8 ng/ml
25 (57)
(n = 92)
Adherence to study medication (%)
≥90% (n = 112)
26 (52)
<90% (n = 58)
18 (53)
Age (%)
<50 years (n = 88)
19 (49)
≥50 years (n = 84)
25 (54)

Placebo (n = 87)

p-Value*

14 (33)
25 (56)

0.03
0.45

13 (33)

0.24

26 (54)

0.80

27 (44)
11 (46)

0.37
0.59

24 (53)
15 (36)

0.67
0.08

*p-Value from bivariate logistic regression within each subgroup.
0.77
0.70
0.89
0.47
0.57
0.81
0.64
0.91
0.65
0.55
0.23
0.26
0.47
0.84
0.58
0.39
0.49

SD, standard deviation.
a
Among participants who were currently on ART.
* p-Values by chi-square tests for categorical and t-tests for continuous
measures.

positive PEth biomarker at enrollment, which suggests
that some women could have exaggerated their drinking
behavior at baseline to enroll in a research study that paid
cash incentives to participants. While PEth is clearly associated with drinking behavior in women at the aggregate
level (Wang et al., 2018), some other studies have reported
inconsistent results for PEth versus self-reported drinking
in women (Littleﬁeld et al., 2017; Papas et al., 2016). It
remains unclear how sensitive or speciﬁc a PEth result is
for an individual woman, or how its test characteristics
may vary according to the time between the last drinking
episode and the PEth assessment (Moore et al., 2018). It
was also notable that the average AUDIT score was 17,
which should correlate strongly with alcohol use disorder, yet only 62% of women met criteria for alcohol use
disorder.

Table 4. Adverse Events Related or Possibly Related to the Study
Medication

# Participant affected
Severe adverse events
Other adverse events (%)
Nausea
Increased appetite
Itchiness
Fatigue
Dizziness
Decreased appetite
Sleepiness
Abdominal pain
Diarrhea
Vomiting
Headache
Nervousness/anxiety
Insomnia
Abnormal
liver
laboratory value
Depression
Constipation
Upset stomach

Naltrexone
(n = 96)

Placebo
(n = 98)

p-Value*

49 (51%)
0

40 (40.8%)
0

0.19
-

22 (22.9)
14 (14.6)
6 (6.3)
8 (8.3)
8 (8.3)
5 (5.2)
7 (7.3)
7 (7.3)
8 (8.3)
7 (8.3)
1 (1.0)
2 (2.1)
2 (2.1)
2 (2.1)

14 (14.3)
11 (11.2)
9 (9.2)
5 (5.1)
4 (4.1)
6 (6.1)
4 (4.1)
3 (3.1)
1 (1.0)
2 (2.0)
6 (6.1)
4 (4.1)
2 (2.0)
1 (1.0)

0.12
0.49
0.44
0.37
0.22
0.78
0.33
0.21
0.02
0.10
0.12
0.68
1
0.62

2 (2.1)
1 (1.0)
0 (0.0)

0 (0.0)
0 (0.0)
1 (1.0)

0.24
0.49
1

*p-Value based on chi-square test.

SUMMARY AND CONCLUSIONS
This study showed that it is feasible to provide oral naltrexone to WLWH who also have a range of other medical and substance use comorbidities and that participating
in a clinical trial with repeated assessments appears to
have an impact on drinking overall. While our study did
not ﬁnd that naltrexone provided superior results than
placebo, reductions in drinking were associated with
improved HIV viral suppression. These data support recommendations to reduce drinking in WLWH infection
and also suggest that continued research is needed to identify new medications or other alcohol interventions that
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Fig. 3. Proportions of participants who had suppressed HIV viral load (<200 copies/ml) among participants who completed the study and had either
had reduced or quit drinking (n=106) or had continued unhealthy alcohol use (n=60) at the 7-month timepoint.

can more eﬀectively help women reduce or stop undesired
alcohol consumption.
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